HC Wainwright Increases Tyra Biosciences (NASDAQ:TYRA) Price Target to $32.00

Tyra Biosciences (NASDAQ:TYRA) had its price target upped by stock analysts at HC Wainwright from $30.00 to $32.00 in a note issued to investors on Monday, Benzinga reports. The firm presently has a “buy” rating on the stock. HC Wainwright’s price objective would suggest a potential upside of 89.24% from the company’s previous close.

Several other equities analysts have also commented on the stock. Piper Sandler assumed coverage on shares of Tyra Biosciences in a research report on Thursday, August 15th. They set an “overweight” rating and a $33.00 price target for the company. Oppenheimer upped their price target on shares of Tyra Biosciences from $25.00 to $33.00 and gave the stock an “outperform” rating in a research report on Thursday, September 19th. Bank of America raised shares of Tyra Biosciences from a “neutral” rating to a “buy” rating and upped their price objective for the stock from $22.00 to $31.00 in a report on Friday, October 18th. Finally, Wedbush reaffirmed an “outperform” rating and issued a $28.00 price objective on shares of Tyra Biosciences in a report on Friday, October 25th. Five investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, Tyra Biosciences presently has a consensus rating of “Buy” and an average target price of $31.40.

Tyra Biosciences Price Performance

TYRA stock opened at $16.91 on Monday. The firm has a fifty day moving average price of $22.84 and a two-hundred day moving average price of $19.91. The firm has a market cap of $893.02 million, a price-to-earnings ratio of -10.01 and a beta of 1.01. Tyra Biosciences has a 1-year low of $10.60 and a 1-year high of $29.60.

Tyra Biosciences (NASDAQ:TYRA) last released its quarterly earnings results on Wednesday, August 7th. The company reported ($0.32) EPS for the quarter, topping the consensus estimate of ($0.41) by $0.09. As a group, analysts expect that Tyra Biosciences will post -1.53 EPS for the current fiscal year.

Insider Buying and Selling at Tyra Biosciences

In other Tyra Biosciences news, CEO Todd Harris sold 10,092 shares of the company’s stock in a transaction dated Monday, September 23rd. The shares were sold at an average price of $24.13, for a total value of $243,519.96. Following the completion of the sale, the chief executive officer now directly owns 1,479,528 shares of the company’s stock, valued at approximately $35,701,010.64. This represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In the last three months, insiders sold 61,403 shares of company stock valued at $1,582,774. 15.40% of the stock is owned by insiders.

Institutional Investors Weigh In On Tyra Biosciences

A number of institutional investors and hedge funds have recently bought and sold shares of TYRA. RA Capital Management L.P. lifted its stake in Tyra Biosciences by 43.9% during the first quarter. RA Capital Management L.P. now owns 10,416,609 shares of the company’s stock valued at $170,832,000 after buying an additional 3,180,155 shares in the last quarter. BVF Inc. IL increased its holdings in shares of Tyra Biosciences by 70.1% in the 1st quarter. BVF Inc. IL now owns 4,661,194 shares of the company’s stock valued at $76,444,000 after purchasing an additional 1,921,599 shares during the period. Perceptive Advisors LLC increased its holdings in shares of Tyra Biosciences by 50.5% in the 2nd quarter. Perceptive Advisors LLC now owns 1,007,367 shares of the company’s stock valued at $16,108,000 after purchasing an additional 338,208 shares during the period. Vanguard Group Inc. increased its holdings in Tyra Biosciences by 18.6% in the first quarter. Vanguard Group Inc. now owns 899,800 shares of the company’s stock worth $14,757,000 after buying an additional 140,833 shares during the last quarter. Finally, Kynam Capital Management LP increased its holdings in Tyra Biosciences by 51.4% in the first quarter. Kynam Capital Management LP now owns 515,190 shares of the company’s stock worth $8,449,000 after buying an additional 175,000 shares during the last quarter. 84.14% of the stock is owned by institutional investors and hedge funds.

About Tyra Biosciences

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.